Breaking News

Akari Therapeutics Opens U.S. Headquarters in Boston

Office to support expanding operations and start of registrational Phase 3 clinical trials.

Akari Therapeutics, a late-stage biotechnology company developing therapies for autoimmune and inflammatory diseases, established a Boston Seaport area office that will be the company’s U.S. headquarters. The office supports Akari’s current expansion of operations in preparation for the start of enrollment in two registrational nomacopan Phase 3 clinical trials in pediatric and adult hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) and the start of PAS-nomacopan c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters